Treatment of postmenopausal osteoporosis with transdermal estrogen.
about
Long term hormone therapy for perimenopausal and postmenopausal womenLong term hormone therapy for perimenopausal and postmenopausal womenHormone replacement therapy for preventing cardiovascular disease in post-menopausal womenLong term hormone therapy for perimenopausal and postmenopausal womenGuidelines on the management of osteoporosis associated with chronic liver diseaseHormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trialsThe Effects of Transdermally Delivered Oleanolic Acid on Malaria Parasites and Blood Glucose Homeostasis in P. berghei-Infected Male Sprague-Dawley RatsLong-term hormone therapy for perimenopausal and postmenopausal women.Long-term recreational gymnastics, estrogen use, and selected risk factors for osteoporotic fractures.Hormone replacement therapy and fractures in older adults.Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline.Determinants of changes in bone mass and femoral neck structure, and physical performance after menopause: a 9-year follow-up of initially peri-menopausal women.Prevention of hip fractures in long-term care: relevance of community-derived data.TGFβ inducible early gene-1 plays an important role in mediating estrogen signaling in the skeletonEtidronate and alendronate in the treatment of postmenopausal osteoporosis.Benefits and risks of hormone replacement therapy in young adult cancer survivors with gonadal failure.The effects of SERMs on the skeleton.Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group.The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers.Skeletal recovery after weaning does not require PTHrP.Selective estrogen receptor modulators--a new age of estrogens in cardiovascular disease?Bone matters: are density increases necessary to reduce fracture risk?Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution.Raloxifene: a review of its use in postmenopausal osteoporosis.Osteoporosis: evaluation and treatment.Update on estrogens and the skeletonExpert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracture.Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents.Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study.Hormones after menopause?Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.Antiaging therapy: an overview.2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.Breaking down bone strength: a perspective on the future of skeletal genetics.Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease.Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling.Design and conduct of clinical trials in hormone replacement therapy.Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture.Diagnosis and treatment of osteoporosis.A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. II. An assessment of treatment effects.
P2860
Q24201974-990213F6-1FA5-46EE-857C-DB821A42C754Q24241279-CE8CAB56-24BD-44CB-94DE-F7390FA1DA05Q24244146-FF7CCCE5-677C-4DEE-8A59-ED4DE1B760ECQ24246577-D4D7D34A-C20D-456E-B1E6-7E23428A83BBQ24685899-21F497F8-F81E-4B51-AFE0-93AFF6EF0693Q24795111-ECBCC04F-0174-4044-A9CB-6EC5E8079145Q28554747-12E63CD4-A733-4236-86EC-4ACE706E50DEQ30238978-A9DB3717-667E-49E3-A080-DAD57BD04CDEQ30732774-299B81FE-D893-4009-9114-C7CC86A94165Q32028226-A467F1FA-FA7B-443A-9EF0-81FE61897151Q32053363-DB7320EC-5F15-4501-BE69-06A351B187E8Q33206783-02FE0EE9-7139-47BC-A0F3-A82BCC23FB22Q33546626-BC0831EC-ADFB-4A2A-A50C-CD36C0CD9F66Q33640377-F369B979-871E-479D-BAA4-33B51FA0F708Q33659364-937EE0AB-AAB6-4280-A747-009D0BA72967Q33684739-35CC40AB-4B79-4354-8569-A37B593E3392Q33757731-24746F1D-97E1-44C2-80D9-09AB699AECB8Q33805259-4F323B60-AD35-4715-8C6A-09D323F47E57Q33814554-26F5AF39-AD07-4AE1-9387-24F03FB4833CQ33817186-579380E9-A72A-4641-9F95-D78D6869EC69Q33841014-0467F236-0EDA-4168-B71B-6BEE86AB28BAQ33855012-CC55609A-E872-4B11-AA14-EA7C7898B29FQ33909569-65EA78F7-8236-4763-A996-9F5E1C991CE1Q34030136-3F238B19-C2BB-416D-AA37-97AA6FD6D7A7Q34031232-4D72ED24-FB56-4C65-89D8-E3ED962DEC10Q34031994-E3982AAF-86E7-440B-8DAF-657875ADBF60Q34063686-042B21AB-DD10-48E1-AC7C-C16BF92A328CQ34087262-1684D30D-72D1-40C0-BB63-B273B4644917Q34216887-BA412B81-4C00-4BE6-8DD7-BB55F25E1C3FQ34267973-B339CF92-09B2-46EB-B06F-572926EC50F9Q34283690-C572D370-7F2E-49FF-8A8E-3D443133B629Q34289602-4D2539AD-9252-437A-BAB5-378FA988F22CQ34300668-DC8958B9-E80C-45A5-8E53-F3376C2BDAEEQ34307011-B0BBE640-FED9-48F7-B34F-2F39DCE0F384Q34377588-2A064956-A0A5-4001-8FC1-3E0619AF53C5Q34384039-4C147AAF-A8F1-4CC6-9223-3F68E394A3C4Q34397332-3A9801B9-8D53-4084-BB0C-24CFF64602C9Q34473262-A026EBD4-EEF9-43E6-AAED-9AF2AE9B9E8BQ34520972-CD04F358-48C6-48E7-8117-60C894463D8BQ34573282-257DD56E-F3AB-4EE1-B79A-59E1A056F127
P2860
Treatment of postmenopausal osteoporosis with transdermal estrogen.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
Treatment of postmenopausal osteoporosis with transdermal estrogen.
@en
Treatment of postmenopausal osteoporosis with transdermal estrogen.
@nl
type
label
Treatment of postmenopausal osteoporosis with transdermal estrogen.
@en
Treatment of postmenopausal osteoporosis with transdermal estrogen.
@nl
prefLabel
Treatment of postmenopausal osteoporosis with transdermal estrogen.
@en
Treatment of postmenopausal osteoporosis with transdermal estrogen.
@nl
P2093
P1476
Treatment of postmenopausal osteoporosis with transdermal estrogen.
@en
P2093
Hodgson SF
Kotowicz MA
O'Fallon WM
P356
10.7326/0003-4819-117-1-1
P407
P577
1992-07-01T00:00:00Z